Julian Sinclair Smith

Sinclair Broadcast Group Announces Annual Diversity Scholarship Submission for 2023, Shaping the Future of Broadcasting

Retrieved on: 
Thursday, January 26, 2023
Other Communications, Publishing, University, Education, Communications, Other Consumer, Women, Philanthropy, TV and Radio, Teens, Men, Media, Family, Other Philanthropy, Entertainment, Consumer, SBGI, Julian Sinclair Smith, Student, Sinclair Broadcast Group, Marketing

Sinclair Broadcast Group (Nasdaq: SBGI) today announced the company’s annual Diversity Scholarship program is now accepting applications for the 2023 school year.

Key Points: 
  • Sinclair Broadcast Group (Nasdaq: SBGI) today announced the company’s annual Diversity Scholarship program is now accepting applications for the 2023 school year.
  • Applicants must be a current college sophomore or junior at an accredited four-year undergraduate college or university in the United States.
  • The annual Sinclair Broadcast Group Diversity Scholarship complements the company’s efforts to bring more diversity to the industry.
  • Additional details on the scholarship and the 2022 winners can be found on the Sinclair Broadcast Group website.

Vipergen and LEO Pharma Partner for DNA Encoded Library (DEL)-Based Drug Discovery for Dermatology Indications

Retrieved on: 
Wednesday, June 15, 2022
Doctor of Philosophy, Leo Pharma, Dels, Technology, Dermatology, Biotechnology, Dermatitis, Skin, Drug discovery, Library, Partnership, BTE, DEL, Patient, Acne, Psoriasis, Julian Sinclair Smith, Fine chemical, EU

COPENHAGEN, Denmark, June 15, 2022 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today a multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications.

Key Points: 
  • COPENHAGEN, Denmark, June 15, 2022 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today a multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications.
  • Under the terms of the agreement, Vipergen will apply its high-fidelity DNA-encoded library (DEL) screening technologies, including its new in-living-cell DEL platform, to discover novel small-molecule compounds that bind to selected LEO Pharma targets.
  • LEO Pharma will select hits for potential development into innovative drugs for dermatology applications.
  • For more details about Vipergen and the YoctoReactor (yR), Binder Trap Enrichment (BTE), and Cellular Binder Trap Enrichment (cBTE) drug discovery technology platforms, please visit www.vipergen.com .

WideOrbit Introduces Automated Addressable Ad Replacement for Live-Streamed Broadcast TV Content

Retrieved on: 
Wednesday, June 1, 2022
ATSC 3.0, Advertising, IBM POWER instruction set architecture, Sinclair Broadcast Group, Spot, Radio, Julian Sinclair Smith, Material, GLOBE, TEGNA, Efficiency, OTT, Atmosphere, SAN, Graham Media Group, Industry, Gray Television, ATSC, CTV, Automation, Television, Video game console, Mobile phone

The newest release of WO Traffic marks a significant milestone in the industry with the introduction of an addressable ad replacement solution that automates the replacement of broadcast spots on live streams with addressable ads.

Key Points: 
  • The newest release of WO Traffic marks a significant milestone in the industry with the introduction of an addressable ad replacement solution that automates the replacement of broadcast spots on live streams with addressable ads.
  • Were excited to introduce our addressable ad replacement solution with the release of WO Traffic v22.0, says Will Offeman, WideOrbit Chief Product Officer.
  • Over 80% of our customers today are streaming their over-the-air content and addressable ad replacement will make it easier for them to take full advantage of revenue opportunities on the stream.
  • WO Traffics addressable ad replacement solution enables a single playlist to be sent to both airtime (over the air) automation and streaming ad servers, with Spot and Material level data.

Vipergen Establishes DNA Encoded Library (DEL)-Based Drug Discovery Partnership with Theseus Pharmaceuticals Focused on Targeted Cancer Therapies

Retrieved on: 
Monday, April 4, 2022
Therapy, Biotechnology, Doctor of Philosophy, BTE, Cancer, Drug discovery, Dels, Julian Sinclair Smith, DEL, TKI, Patient, Pharmaceutical industry, EU

COPENHAGEN, Denmark, April 4, 2022 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a drug discovery agreement with Theseus Pharmaceuticals, a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies.

Key Points: 
  • COPENHAGEN, Denmark, April 4, 2022 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a drug discovery agreement with Theseus Pharmaceuticals, a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies.
  • Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target.
  • Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell.
  • For more details about Vipergen and the YoctoReactor (yR), Binder Trap Enrichment (BTE), and Cellular Binder Trap Enrichment (cBTE) drug discovery technology platforms, please visit www.vipergen.com .

TicketSmarter and Sinclair Sports Group Enter Into Multi-Year Agreement

Retrieved on: 
Thursday, January 27, 2022
Online Retail, Entertainment, Retail, Sports, TV and Radio, General Entertainment, General Sports, Rose Bowl (stadium), St. Jude Children's Research Hospital, DGLY, University, Partnership, Organization, Sinclair Broadcast Group, Tennis Channel, Switzerland Digital Sales, Organic, Sale, Bally Sports, Sport, Athlete, ESPN Events, NASDAQ, ESPN, Twitter, 2019 Digital Ally 400, SBGI, Jim Valvano, Stadium, Julian Sinclair Smith, Hospital, Mohammed V Foundation for Solidarity, SVP, CEO, Birmingham Bowl, Television set, Online shopping, Sinclair Sports Group, TicketSmarter, SINCLAIR SPORTS GROUP, TICKETSMARTER

TicketSmarter and Sinclair Sports Group, a sales division of Sinclair Broadcast Group, Inc., today announced a new, multi-year agreement for TicketSmarter to become the official ticket provider of the non-linear digital platforms for Bally Sports and Tennis Channel, and the Sinclair Broadcast Group station websites.

Key Points: 
  • TicketSmarter and Sinclair Sports Group, a sales division of Sinclair Broadcast Group, Inc., today announced a new, multi-year agreement for TicketSmarter to become the official ticket provider of the non-linear digital platforms for Bally Sports and Tennis Channel, and the Sinclair Broadcast Group station websites.
  • TicketSmarter is a ticket resale marketplace with seats for more than 125,000 live events and 48 million tickets for sale.
  • This partnership was a no-brainer for us given Sinclair Sports Groups reach and reputation in broadcasting, said Jeff Goodman, CEO, TicketSmarter.
  • Sinclair Sports Group a sales division of Sinclair Broadcast Group, Inc. (NASDAQ: SBGI) is a national, regional, and omnichannel sports solution, providing brands the ability to reach fans 365 days a year.

Vipergen Establishes Research Partnership with Bayer to Discover Novel Compoundsfor Pharmaceuticals and More Sustainable Crop Protection Solutions

Retrieved on: 
Tuesday, December 21, 2021
Doctor of Philosophy, BTE, Health, Social innovation, Technology, Bayer, Trust, SVP, Dels, Biotechnology, Research, Partnership, Solution, DEL, Julian Sinclair Smith, Agriculture, Library, Corporation, Crop protection, Group, Ageing, Growth, Pharmaceutical industry, Fine chemical, EU

COPENHAGEN, Denmark, Dec. 21, 2021 /PRNewswire/ --Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target research agreement with Bayer to discover novel small-molecule lead compounds for development of pharmaceuticals and more sustainable crop protection solutions.

Key Points: 
  • COPENHAGEN, Denmark, Dec. 21, 2021 /PRNewswire/ --Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target research agreement with Bayer to discover novel small-molecule lead compounds for development of pharmaceuticals and more sustainable crop protection solutions.
  • Under the terms of the agreement, Vipergen will apply its new in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to selected Bayer protein targets.
  • Bayer will select potential drug and crop protection development candidates based on the hits generated by Vipergen's technology.
  • Bayer will retain exclusive rights to globally commercialize all products resulting from the collaboration.

Vipergen Establishes Research Partnership with Aligos Therapeutics Focused on DNA Encoded Library (DEL)-Based Drug Discovery for Viral Infections and Liver Diseases

Retrieved on: 
Tuesday, November 23, 2021
Coronavirus, Hepatitis, Julian Sinclair Smith, Institute of Liver and Biliary Sciences, Doctor of Philosophy, Therapy, DEL, Dels, Nasdaq, Biotechnology, NASH, BTE, Jacob Aligo, Drug discovery, Pharmaceutical industry

COPENHAGEN, Denmark, Nov. 23, 2021 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with Aligos Therapeutics, Inc. (Nasdaq: ALGS).

Key Points: 
  • COPENHAGEN, Denmark, Nov. 23, 2021 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with Aligos Therapeutics, Inc. (Nasdaq: ALGS).
  • Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that bind to selected Aligos protein targets.
  • Aligos will select hits for development into novel therapeutics for viral and liver diseases.
  • For more details about Vipergen and the YoctoReactor (yR), Binder Trap Enrichment (BTE), and Cellular Binder Trap Enrichment (cBTE) drug discovery technology platforms, please visit www.vipergen.com .

Vipergen Establishes Research Partnership with ALK Focused on DNA-Encoded Library (DEL)-Based Drug Discovery for Allergy Immunotherapies

Retrieved on: 
Monday, November 15, 2021
Doctor of Philosophy, DEL, Technology, Dels, Partnership, Biotechnology, Therapy, Allergy, Drug discovery, Julian Sinclair Smith, BTE, OMX, ALK, Pharmaceutical industry

COPENHAGEN, Denmark, Nov. 15, 2021 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with the allergy company ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF).

Key Points: 
  • COPENHAGEN, Denmark, Nov. 15, 2021 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with the allergy company ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF).
  • Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that bind to selected ALK protein targets.
  • ALK will select hits for development into novel therapeutics for the prevention and treatment of a broad range of allergies.
  • Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell.

BASF And Vipergen Accelerate Targeted Research And Development Of Sustainable Crop Protection Products

Retrieved on: 
Thursday, October 21, 2021
Farmer, DEL, Research, Biotechnology, Technology, BTE, Pest control, Partnership, Crop protection, Agriculture, Library, Senior, Protein, Dels, Seed, Julian Sinclair Smith, Environment, BASF, Cell, Solution, Population, DNA, Fine chemical

BASF partners with Vipergen, a global leader in research services, to apply their technology to discover new active ingredients for sustainable crop protection products more efficiently and quickly.

Key Points: 
  • BASF partners with Vipergen, a global leader in research services, to apply their technology to discover new active ingredients for sustainable crop protection products more efficiently and quickly.
  • "The collaboration with Vipergen will complement our set of tools aimed at developing novel, world-class, sustainable crop protection solutions for a connected offer that will benefit farmers, consumers and the environment," said Juergen Huff, Senior Vice President, Research and Development Crop Protection at BASF Agricultural Solutions.
  • "We are excited to partner with BASF to drive innovation for sustainable agriculture," said Nils Hansen, Chief Executive Officer of Vipergen.
  • "Applying our Cellular Binder Trap Enrichment technology to screen DNA-encoded libraries in living cells will quickly provide high-quality hits that BASF can use to develop new sustainable crop protection products."

Vipergen Establishes Research Partnership with PhoreMost Focused on DNA Encoded Library (DEL)-Based Drug Discovery

Retrieved on: 
Tuesday, September 14, 2021
Dels, Drug discovery, Biotechnology, DEL, Julian Sinclair Smith, Doctor of Philosophy, Patient, BTE, Therapy, Lists of World Heritage Sites, Cancer, Pharmaceutical industry

COPENHAGEN, Denmark, Sept. 14, 2021 /PRNewswire/ --Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with PhoreMost.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 14, 2021 /PRNewswire/ --Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with PhoreMost.
  • Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that bind to selected PhoreMost protein targets.
  • Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell.
  • For more details about Vipergen and the YoctoReactor (yR), Binder Trap Enrichment (BTE), and Cellular Binder Trap Enrichment (cBTE) drug discovery technology platforms, please visit www.vipergen.com .